ARQ197(ARQ-197; Tivantinib)是一种高效选择性的、可口服的非ATP竞争型的c-Met抑制剂, 对c-Met的Ki值是0.355 μM，对EGFR、InsR、PDGFRα、FGFR1/4没有抑制作用，可诱导G2/M期细胞阻滞和细胞凋亡。 

参考文献

[1]. Ryohei Katayama, et al. Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Research, 2013, 73(10): 3087-3097.

[2]. Sara Previdi, et al. Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown. Mol Cancer Ther, 2011, 11(1):214-23.

[3]. Munshi N, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010 Jun;9(6):1544-53.

冰袋运输。粉末直接保存于-20℃，有效期2年。溶于DMSO。建议分装后-20℃避光保存，避免反复冻融。